New York Heart Association Functional Class and Implantable Cardioverter-Defibrillator in Non-Ischaemic Heart Failure with Reduced Ejection Fraction: Extended Follow-Up of the DANISH Trial
European Journal of Heart Failure · 2024
DOI: 10.1002/ejhf.3239 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Heart Failure, 2024. Verfasst von Munise N Karacan und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Defibrillators, Implantable, Heart Failure, Stroke Volume. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Aims
Current guidelines recommend implantable cardioverter-defibrillator (ICD) therapy in patients with heart failure, a left ventricular ejection fraction of ≤35%, and New York Heart Association (NYHA) class II–III. However, the evidence regarding the benefit of primary prevention ICD is less consistent in patients with NYHA class III. We investigated the long-term effects of primary prevention ICD implantation according to NYHA class in an extended follow-up study of the DANISH trial. Methods and results The DANISH trial randomized 1116 patients with non-ischaemic heart failure with reduced ejection fraction (HFrEF) to ICD implantation or usual care. Outcomes were analysed according to NYHA class at baseline (NYHA class II and III/IV). The primary outcome was all-cause mortality. Of the 1116 patients randomized in the DANISH trial, 597 (53.5%) were in NYHA class II at baseline, 505 (45.3%) in NYHA class III, and 14 (1.3%) in NYHA class IV. During a median follow-up of 9.5 years, NYHA class III/IV, compared with NYHA class II, were associated with a greater long-term rate of all-cause mortality (hazard ratio [HR] 1.52, 95% confidence interval [CI] 1.20–1.93) and cardiovascular death (HR 1.95 [1.47–2.60]). ICD implantation, compared with usual care, did not reduce the long-term rate of all-cause mortality (all participants: HR 0.89 [95% CI 0.74–1.08]; NYHA class II: HR 0.85 [0.64–1.13]; NYHA class III/IV: HR 0.89 [0.69–1.14]; pinteraction = 0.78) or cardiovascular death (all participants: HR 0.87 [95% CI 0.70–1.09]; NYHA class II: HR 0.78 [0.54–1.12]; NYHA class III/IV: HR 0.89 [0.67–1.19]; pinteraction = 0.58), irrespective of NYHA class. Similarly, NYHA class did not modify the beneficial effects of ICD implantation on sudden cardiovascular death (all participants: HR 0.60 [95% CI 0.40–0.92]; NYHA class II: HR 0.73 [0.40–1.36]; NYHA class III/IV: HR 0.52 [0.29–0.94]; pinteraction = 0.39).
Conclusions
In patients with non-ischaemic HFrEF, ICD implantation, compared with usual care, did not reduce the overall mortality rate, but it did reduce sudden cardiovascular death, regardless of baseline NYHA class. Clinical Trial Registration: ClinicalTrials.gov NCT00542945.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
- Department of Cardiology, Copenhagen University Hospital - Bispebjerg and Frederiksberg, Copenhagen, Denmark.
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
- Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.
- Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
- Department of Cardiology, Copenhagen University Hospital-Herlev and Gentofte, Hellerup, Denmark.
Zitieren
APA
Karacan, M. N., Doi, S. N., Yafasova, A., Thune, J. J., Nielsen, J. C., Haarbo, J., Bruun, N. E., Gustafsson, F., Eiskjær, H., Hassager, C., Svendsen, J. H., Høfsten, D. E., Pehrson, S., Køber, L., & Butt, J. H. (2024). New York Heart Association Functional Class and Implantable Cardioverter-Defibrillator in Non-Ischaemic Heart Failure with Reduced Ejection Fraction: Extended Follow-Up of the DANISH Trial. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.3239
Vancouver
Karacan MN, Doi SN, Yafasova A, Thune JJ, Nielsen JC, Haarbo J, et al. New York Heart Association Functional Class and Implantable Cardioverter-Defibrillator in Non-Ischaemic Heart Failure with Reduced Ejection Fraction: Extended Follow-Up of the DANISH Trial. European Journal of Heart Failure. 2024. doi:10.1002/ejhf.3239
BibTeX
@article{Karacan2024,
author = {Karacan, Munise N and Doi, Seiko N and Yafasova, Adelina and Thune, Jens Jakob and Nielsen, Jens C and Haarbo, Jens and Bruun, Niels E and Gustafsson, Finn and Eiskjær, Hans and Hassager, Christian and Svendsen, Jesper H and Høfsten, Dan E and Pehrson, Steen and Køber, Lars and Butt, Jawad H},
title = {New York Heart Association Functional Class and Implantable Cardioverter-Defibrillator in Non-Ischaemic Heart Failure with Reduced Ejection Fraction: Extended Follow-Up of the DANISH Trial},
journal = {European Journal of Heart Failure},
year = {2024},
doi = {10.1002/ejhf.3239}
}
EUVIMED